Eugene Lin, MD, MS, FASN

Associate Professor of Medicine and Health Policy and Management

Image of Eugene Lin, MD, MS, FASN
Is this your profile? Click to edit

Overview

Eugene Lin, MD, MS, is a nephrologist and health services researcher with a focus on economic policies pertaining to kidney disease. He is a nationally recognized expert on the impact of public policy and federal regulation on kidney care, the provision of dialysis in public and private insurance markets, and transitions of care for patients with kidney disease. He is an NIH funded investigator, and his work has been published in leading health policy and medical journals, including JAMA, Health Affairs, and JAMA Internal Medicine.

In addition to his academic roles at USC, he currently serves on the National Kidney Foundation’s Scientific Advisory Board and the American Society of Nephrology’s Transplant Policy Committee. He has also participated as a key stakeholder in multiple Technical Expert Panels for the Centers for Medicare and Medicaid Services.

Dr. Lin completed a postdoctoral fellowship in nephrology at the Stanford School of Medicine and completed his Internal Medicine residency at the Hospital of the University of Pennsylvania.

Education and Training

  • USC, Los Angeles, CA — Visiting Scholar — 2018
  • Stanford University School of Medicine, Palo Alto, CA — Fellow — 2018 — Nephrology
  • Stanford University, Stanford, CA — M.S. — 2017 — Health Services Research
  • Hospital of the University of Pennsylvania, Philadelphia, CA — Resident — 2014 — Internal Medicine
  • Hospital of the University of Pennsylvania, Philadelphia, CA — Intern — 2012
  • Baylor College of Medicine, Houston, TX — M.D. — 2011 — Medicine
  • Stanford University, Stanford, CA — B.S. — 2006 — Biology, minor in Mathematics

Research Funding

  • Elucidating the Mechanisms of Racial and Ethnic Disparities in Dialysis Quality
    NIH · R01DK137223 · Sep 1, 2023 – Jun 30, 2028 · Role: Principal Investigator
  • Comparing Dialysis Provision and Outcomes Between Medicare Advantage and Fee-for-Service Medicare
    NIH · R03DK131239 · Jul 1, 2022 – Jun 30, 2024 · Role: Principal Investigator
  • The Impact of Medicare Advantage on Patients with End-Stage Kidney Disease
    American Society of Nephrology (KidneyCure) · Jul 1, 2021 – Jun 30, 2023 · Role: Principal Investigator
  • Investigating the Economic and SocialDeterminants of Home Dialysis Drop-Out
    NIH · K08DK118213 · Aug 15, 2018 – May 31, 2024 · Role: Principal Investigator
  • Investigating the Appropriateness of 30-Day Rehospitalizations in Dialysis Patients
    NIH · F32DK107123 · Jul 20, 2015 – Jul 19, 2018 · Role: Principal Investigator

Research Keywords

  • Dialysis Delivery
  • Multidisciplinary Care in Kidney Disease
  • Value-Based Purchasing
  • Medicare Payment Policy
  • Decision Analysis

Publications

  • Care Continuity, Nephrologists’ Dialysis Facility Preferences, and Outcomes. JAMA Health Forum. 2025 Apr 04; 6(4):e250423.. View in PubMed
  • Association of Kidney Function With Inpatient Mortality and Morbidity After Cardiac Surgery. Ann Thorac Surg Short Rep. 2024 Dec; 2(4):877-883.. View in PubMed
  • Examining chronic kidney disease screening frequency among diabetics: a POMDP approach. Health Care Manag Sci. 2024 Sep; 27(3):391-414.. View in PubMed
  • Disparities in the Timing of Preoperative Hemodialysis Among Patients With End-Stage Kidney Disease. JAMA Netw Open. 2023 07 03; 6(7):e2326326.. View in PubMed
  • On the path to individualizing care with incremental-start hemodialysis. J Nephrol. 2023 07; 36(6):1505-1508.. View in PubMed
  • Cataract Surgery in the Medicare Merit-Based Incentive Payment System: Episode-Based Cost Measure Development and Evaluation. Ophthalmol Sci. 2023 Dec; 3(4):100315.. View in PubMed
  • Preoperative Hemodialysis Timing and Postoperative Mortality in Patients With End-stage Kidney Disease-Reply. JAMA. 2023 03 21; 329(11):939-940.. View in PubMed
  • Nephrology and the US News and World Report Hospital-Based Specialty Rankings. Kidney Med. 2023 Apr; 5(4):100620.. View in PubMed
  • How Frequently Should We Screen for Hepatitis C in US Hemodialysis Centers? Evaluating the Cost-Effectiveness of Different Strategies. J Am Soc Nephrol. 2023 02 01; 34(2):193-194.. View in PubMed
  • Racial disparities and standard treatment in locally advanced rectal cancer: a National Cancer Database study. J Gastrointest Oncol. 2022 Dec; 13(6):2922-2937.. View in PubMed